Cell adhesion inhibitors

Details Cell adhesion inhibitors Cell adhesion inhibitors

2005-04-05

2005-04-05

Carlson, Karen Cochrane (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S016700, C514S017400, C514S018700, C530S326000, C530S327000, C530S328000, C530S300000, C424S185100, C424S278100

Reexamination Certificate

active

06875743

ABSTRACT:
The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.

REFERENCES:
patent: 4725583 (1988-02-01), Luly et al.
patent: 4826815 (1989-05-01), Luly et al.
patent: 5260277 (1993-11-01), McKenzie
patent: 5314902 (1994-05-01), Tjoeng et al.
patent: 5434188 (1995-07-01), Boschelli et al.
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 6239108 (2001-05-01), Lin et al.
patent: 6248713 (2001-06-01), Lin et al.
patent: 6596687 (2003-07-01), Lin et al.
patent: 43 09 867 (1994-09-01), None
patent: 0 021 234 (1981-01-01), None
patent: 0 460 679 (1991-12-01), None
patent: 0 519 748 (1992-12-01), None
patent: 0 565 896 (1993-10-01), None
patent: WO 8909786 (1989-10-01), None
patent: WO 9109837 (1991-07-01), None
patent: WO 92 00995 (1992-01-01), None
patent: WO 9200995 (1992-01-01), None
patent: WO 92 08464 (1992-05-01), None
patent: WO 9208464 (1992-05-01), None
patent: WO 9308823 (1993-05-01), None
patent: WO 9309795 (1993-05-01), None
patent: WO 9312809 (1993-07-01), None
patent: WO 93 12809 (1993-07-01), None
patent: WO 9402445 (1994-02-01), None
patent: WO 9415958 (1994-07-01), None
patent: WO 94 23714 (1994-10-01), None
patent: WO 9423714 (1994-10-01), None
patent: WO 9515973 (1994-12-01), None
patent: WO 9515973 (1995-06-01), None
U.S. patent application No. 09/482,296; Jan. 13, 2000.
Abraham, W.M., et al., “I4-Intergrins Mediate Antigen-induced Late Bronchial Responses and Prolonged Airway Hyperresponsiveness in Sheep”, Journal of Clinical Investigation, vol. 93, No. 2, pp. 776-787 (1994).
Bajusz, et al., “Design and synthesis of Peptide Inhibitors of Blood Coagulation”, Folia Haematol, Leipzig, vol. 109 pp: 16-21 (1982).
Baldwin, J.E., et al., CA 108: 127408t, 1998.
Chen, S.T., et al., CA 115:159749r, 1991.
Chisholm, P.L., et al., “Monoclonal antibodies to the integrin α-4 subunit inhibit the murine contact hypersensitivity response”, Eur. J. Immunol. vol. 23, pp. 682-688, (1993).
Elices, M.J., et al., “Expression and Functional Significance of Alternatively Spliced CS1 Fibronectin in Rheumatoid Arthritis Microvasculature,”, Journal of Clinical Investigation, vol. 93, No. 1, pp. 405-416 (1994).
Ferguson, T.A., et al., “Two integrin-binding peptides abrogate T cell-mediated immune responses in vivo”, Proc. Natl. Acad. Sci. USA, vol. 88, pp. 8072-8076 (1991).
Ferguson, T.A. et al., “Antigen-Independent Processes in Antigen-Specific Immunity”, Journal of Immunology, vol. 150, No. 4, pp. 1172-1182 (1993).
Goodman, et al., “Synthesis and Conformation of Sequential Polypeptides of L-Alanine and J-Aminobutyric Acid”, Macromolecules, vol. 9, No. 1, pp. 1-6, (1976).
Goodman & Gilman's, “The Pharmacological Basis of Therapeutics”, 6thEdition, MacMillan Publishing, Inc., Appendix 3, pp: 1738-1740 (1980).
Greenstein et al., “Chemistry of the Amino Acids,” John Wiley and Sons, Inc., vol. 2, pp 1162-1186.
Gruszecki, W., et al., “Diacylamines—perfekte Acylierungsmittel für die Peptidsynthesis”, Liebigs Ann. Chem., pp 331-336, 1988.
Helmer, M.E., “VLA Proteins in the Integrin Family: Structures, Functions, and their Role in Leukocytes”, Annual Review of Immunology, vol. 8, pp. 365-400 (1990).
Jiang, J., et al., “Approaches Toward the Total Synthesis of Astins A, B, and C”, Tetrahedron Letters, vol. 35, No. 14, pp 2121-2124, (1994).
Kim, et al., “Inhibition of125I-Labeled Ristocetin Binding toMicrococcus luteusCells by the Peptides Related to Bacterial Cell Wall Mucopeptide Precursors: Quantitative Structure-Activity Relationships”, J. Med. Chem., vol. 32, No. 1, pp. 84-93 (1989).
Komoriya, A., et al., “The Minimal Essential Sequence for a Major Cell Type-specific Adhesion Site (CSI) within the Alternatively Spliced Type III Connecting Segment Domain of Fibronectin Is Leucine-Aspartic Acid-Valine”, Journal of Biological Chemistry, vol. 266, No. 23, pp. 15075-15079 (1991).
Lampi, et al., CA 118; 73614t, 1993.
Lobb, R.R. and Hemler, M.E., “The Pathophysiologic Role of α4 Integrins In Vivo”, The American Society for Clinical Investigation, Inc., vol. 94, pp. 1722-1728 (1994).
Molossi, S., et al., “Blockade of Very Late Antigen-4 Integrin Binding of Fibronectin with Connecting Segment-1 Peptide Reduces Accelerated Coronary Arteriopathy in Rabbit Cardiac Allografts”, The American Society for Clinical Investigation, Inc., vol., 95, pp. 2601-2610 (1995).
Morales-Ducret, J., et al., “α4/β1Integrin (VLA-4) Ligands in Arthritis, Vascular Cell Adhesion Molecule-Expression in Synovium and on Fibroblast-Like Synoviocytes”, Journal of Immunology, vol. 149, No. 4, pp. 1424-1431 (1992).
Narumiya, et al., “Pre-B Cells Adhere to Fibronectin Via Interactions of Intergrin α5/αv with RGDS as well as of Integrin α4 with two Distinct V Region Sequences at its Different Binding Sites”, International Immunology, vol. 6, No. 1 pp: 139-147 (1994).
Nowlin, D.M., et al. “A Novel Cyclic Peptide Inhibits α4β1 and α5β1 Integrin-mediated Cell Adhesion”, Journal of Biological Chemistry, vol. 268, No. 27, pp. 20352-20359 (1993).
Sawyer, “Peptidomimetic Design and Chemical Approaches to Peptide Metabolism”, Peptide-Based Drug Design, American Chemical Society, Washington, DC, Chapter 17, pp. 387-410 (1995).
Subasinghe, et al., “Synthesis and Acyclic and Dehydroaspartic Acid Analogues of Ac-Asp-Glu-OH and Their Inhibition of Rat Brain N-Acetylated I-Linked Acidic Dipeptidase (NAALA Dipeptidase)”, Journal of Medicinal Chemistry, vol. 33, No. 10, pp. 2734-2744 (1990).
Thierry et al., “Synthesis and Activity of NAcSerAspLysPro Analogues on Cellular Interactions between T-Cell and Erythrocytes in ROAette Formation,” Journal of Medical Chemistry, 1990, vol. 33, pp. 2122-2127.
Wayner, E.A. and Kovach, N.L., “Activation-dependent recognition by Hematopoietic Cells of the LDV Sequence in the V Region of Fibronectin”, The Journal of Cell Biology, vol. 116, No. 2, pp. 489-497 (1992).
Yednock, T.A., et al, “Prevention of Experimental Autoimmune Encephalomyelitis by Antibodies against α4β1 Integrin”, Nature, vol. 356, No. 6364, pp. 63-66 (1992).
T.K. Sawyer; “Peptidomimetic Design and Chemical Approaches to Peptide Metabolism”, Peptide-Based Drug Design, American Chemical Society, Washington DC, Chapter 17, pp. 387-410 (1995).
“Synthesis and Activity of NAcSerAspLysPro Analogues on Cellular Interactions between T-Cell and Erythrocytes in Rosette Formation,” Thierry et al., Journal of Medical Chemistry, 1990, vol. 33, pp 2122-2127.
“Chemistry of the Amino Acids,” Greenstein et al., John Wiley and Sons, Inc., vol. 2, pp 1162-1186.
“Inhibition of125I-Labeled Ristocetin Binding to Micrococcus Luteus Cells by the Peptides Related to Bacterial Cell Wall Mucopeptide Precursors: Quantitative Structure-Activity Relationships,” Journal Medical Chemistry, 1989, vol. 32, pp 85-93.
Abraham et al., “α4-Integrins Mediate Antigen-induced Late Bronchial Responses and Prolonged Airway Hyperresponsiveness in Sheep”,The Journal of Clinical Investigation, 93:776-787, 1994.
Bajusz et al., “Design and Synthesis of Peptide Inhibitors of Blood Coagulation”,Folia Haematol. Leipzig, 109:16-21, 1982.
Baldwin et al., CA 108: 127408t, 1988.
Chen et al., AAPP 115: 1

Affiliated with

Also associated with

Rating

Cell adhesion inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cell adhesion inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell adhesion inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3401791